IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$173.24 1.73 (1.01 %)
(As of 01/16/2018 12:52 PM ET)
Previous Close$171.51
Today's Range$170.04 - $173.82
52-Week Range$116.54 - $173.82
Volume632,900 shs
Average Volume482,989 shs
Market Capitalization$15.37 billion
P/E Ratio56.25
Dividend YieldN/A
Beta0.42

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Medical Equipment & Supplies
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:IDXX
CUSIP45168D10
Phone+1-207-5560300

Debt

Debt-to-Equity Ratio-12.48%
Current Ratio0.95%
Quick Ratio0.77%

Price-To-Earnings

Trailing P/E Ratio56.2467532467533
Forward P/E Ratio53.47
P/E Growth2.34

Sales & Book Value

Annual Sales$1.78 billion
Price / Sales8.51
Cash Flow$3.42 per share
Price / Cash50.67
Book Value($1.21) per share
Price / Book-143.17

Profitability

Trailing EPS$3.08
Net Income$222.04 million
Net Margins14.55%
Return on Equity-336.64%
Return on Assets16.63%

Miscellaneous

Employees7,365
Outstanding Shares87,220,000

IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has approved a stock buyback program on Sunday, June 4th 2017, which authorizes the company to repurchase 3,000,000 shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Tuesday, October, 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.74 by $0.05. The company had revenue of $492 million for the quarter, compared to analysts' expectations of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 EPS. View IDEXX Laboratories' Earnings History.

When will IDEXX Laboratories make its next earnings announcement?

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for IDEXX Laboratories.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY18 earnings guidance on Tuesday, October, 31st. The company provided earnings per share (EPS) guidance of $3.50-$3.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.54. The company issued revenue guidance of $2.14-$2.18 billion, compared to the consensus revenue estimate of $2.14 billion.IDEXX Laboratories also updated its FY17 guidance to $3.22-$3.26 EPS.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2018?

7 equities research analysts have issued twelve-month price targets for IDEXX Laboratories' stock. Their forecasts range from $118.00 to $200.00. On average, they expect IDEXX Laboratories' share price to reach $176.33 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

What are Wall Street analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "Over the last six months, IDEXX has been trading below the broader industry. Also, the company’s high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation is also a concern. On a positive note, IDEXX continues to demonstrate solid growth globally on strong international expansion. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently widened its cloud technology portfolio by adding rVetLink.  Solid organic revenue growth along with a raised guidance for 2017 buoy optimism." (10/24/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer (Age 60)
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer (Age 54)
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President (Age 53)
  • Jay Mazelsky, Executive Vice President (Age 56)
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary (Age 58)
  • William T. End, Lead Independent Director (Age 69)
  • Bruce L Claflin, Independent Director (Age 65)
  • Stuart M. Essig Ph.D., Independent Director (Age 55)
  • Rebecca M. Henderson Ph.D., Independent Director (Age 56)
  • Daniel M. Junius, Independent Director (Age 64)

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.07%), Franklin Street Advisors Inc. NC (0.05%), Bath Savings Trust Co (0.03%), DnB Asset Management AS (0.03%), Exxonmobil Investment Management Inc. TX (0.02%) and Capital Investment Services of America Inc. (0.00%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Exxonmobil Investment Management Inc. TX, Bath Savings Trust Co, Nisa Investment Advisors LLC and Capital Investment Services of America Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

Who bought IDEXX Laboratories stock? Who is buying IDEXX Laboratories stock?

IDEXX Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC and DnB Asset Management AS. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $173.24.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $15.10 billion and generates $1.78 billion in revenue each year. The company earns $222.04 million in net income (profit) each year or $3.08 on an earnings per share basis. IDEXX Laboratories employs 7,365 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is 1 Idexx Dr, WESTBROOK, ME 04092-2041, United States. The company can be reached via phone at +1-207-5560300 or via email at [email protected]


MarketBeat Community Rating for IDEXX Laboratories (IDXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  433
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IDEXX Laboratories (NASDAQ:IDXX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.332.332.00
Ratings Breakdown: 2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $176.33$171.60$171.60$161.00
Price Target Upside: 1.79% upside7.45% upside7.94% upside3.30% downside

IDEXX Laboratories (NASDAQ:IDXX) Consensus Price Target History

Price Target History for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ:IDXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Piper Jaffray CompaniesInitiated CoverageOverweight$200.00MediumView Rating Details
12/8/2017AegisReiterated RatingSellLowView Rating Details
10/24/2017Stifel NicolausReiterated RatingBuy$185.00N/AView Rating Details
10/6/2017Canaccord GenuityReiterated RatingBuy$180.00N/AView Rating Details
8/23/2017Bank of AmericaUpgradeNeutral -> Buy$175.00LowView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

IDEXX Laboratories (NASDAQ:IDXX) Earnings History and Estimates Chart

Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.73N/AView Earnings Details
10/31/2017Q3 2017$0.74$0.79$492.94 million$492.00 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
10/22/2010Q3 2010$0.28$0.29ViewN/AView Earnings Details
7/23/2010Q2 2010$0.31$0.31ViewN/AView Earnings Details
4/23/2010Q1 2010$0.25$0.28ViewN/AView Earnings Details
1/29/2010Q4 2009$0.23$0.26ViewN/AView Earnings Details
10/23/2009Q3 2009$0.23$0.26ViewN/AView Earnings Details
7/24/2009Q2 2009$0.27$0.28ViewN/AView Earnings Details
4/24/2009Q1 2009$0.19$0.22ViewN/AView Earnings Details
1/30/2009Q4 2008$0.21$0.22ViewN/AView Earnings Details
10/24/2008Q3 2008$0.20$0.21ViewN/AView Earnings Details
7/25/2008Q2 2008$0.28$0.32ViewN/AView Earnings Details
4/25/2008Q1 2008$0.20$0.21ViewN/AView Earnings Details
1/25/2008Q4 2007$0.20$0.20ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

IDEXX Laboratories (NASDAQ:IDXX) Earnings Estimates

2018 EPS Consensus Estimate: $3.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.74$0.81$0.78
Q2 20182$1.05$1.09$1.07
Q3 20182$0.88$0.89$0.89
Q4 20182$0.77$0.83$0.80
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for IDEXX Laboratories (NASDAQ:IDXX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

IDEXX Laboratories (NASDAQ IDXX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 86.66%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ IDXX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/11/2018Jonathan W AyersCEOSell2,160$167.03$360,784.801,077,112View SEC Filing  
1/9/2018Jonathan W AyersCEOSell18,000$165.15$2,972,700.001,077,112View SEC Filing  
11/30/2017Giovani TwiggeInsiderSell2,000$156.07$312,140.00View SEC Filing  
11/16/2017Jonathan W AyersCEOSell18,000$153.61$2,764,980.001,064,573View SEC Filing  
11/14/2017Jonathan W AyersCEOSell18,000$148.35$2,670,300.001,064,573View SEC Filing  
11/7/2017Jonathan W AyersChairmanSell54,000$151.32$8,171,280.001,064,573View SEC Filing  
11/3/2017Jonathan W AyersCEOSell18,000$153.75$2,767,500.001,064,573View SEC Filing  
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.001,044,034View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.2417,274View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.0817,274View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.001,043,034View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.001,043,034View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.001,043,034View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.001,039,034View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.003,344View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.001,032,994View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.0045,256View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.001,024,994View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.0021,552View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.001,135View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00995,947View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.3645,235View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.005,495View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.481,001,043View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.161,001,043View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.0032,783View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.0048,654View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.3216,678View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.8813,484View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.0053,564View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.8863,578View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.0040,011View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.0822,298View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.1032,461View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.0022,048View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.0021,450View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.0021,793View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.2439,654View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.0022,593View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.005,000View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.0011,976View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24389,665View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62377,211View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.001,000View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08365,389View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.003,000View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.8011,566View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.528,989View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

IDEXX Laboratories (NASDAQ IDXX) News Headlines

Source:
DateHeadline
IDEXX Launches Catalyst SDMA for Veterinary Renal Disorder - NasdaqIDEXX Launches Catalyst SDMA for Veterinary Renal Disorder - Nasdaq
www.nasdaq.com - January 15 at 3:37 PM
IDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 2,160 SharesIDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 2,160 Shares
www.americanbankingnews.com - January 11 at 6:58 PM
Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) StockJonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock
www.americanbankingnews.com - January 11 at 6:38 PM
IDEXX to Introduce Applied BioCodes Innovative Multiplex Technology Across Global Reference Laboratory Network - PR Newswire (press release)IDEXX to Introduce Applied BioCode's Innovative Multiplex Technology Across Global Reference Laboratory Network - PR Newswire (press release)
www.prnewswire.com - January 9 at 3:37 PM
IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test - PR Newswire (press release)IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test - PR Newswire (press release)
www.prnewswire.com - January 9 at 3:37 PM
IDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA TestIDEXX Launches SDMA in the Point of Care with IDEXX Catalyst® SDMA Test
finance.yahoo.com - January 8 at 8:52 AM
IDEXX to Introduce Applied BioCode’s Innovative Multiplex Technology Across Global Reference Laboratory NetworkIDEXX to Introduce Applied BioCode’s Innovative Multiplex Technology Across Global Reference Laboratory Network
finance.yahoo.com - January 8 at 8:52 AM
IDEXX Laboratories Announces Estimated Impact of U.S. Tax ReformIDEXX Laboratories Announces Estimated Impact of U.S. Tax Reform
finance.yahoo.com - January 6 at 10:02 AM
BidaskClub Upgrades IDEXX Laboratories (IDXX) to "Hold"BidaskClub Upgrades IDEXX Laboratories (IDXX) to "Hold"
www.americanbankingnews.com - January 6 at 9:56 AM
IDEXX Labs (IDXX) Reports Estimated Impact of US Tax Reform - StreetInsider.comIDEXX Labs (IDXX) Reports Estimated Impact of US Tax Reform - StreetInsider.com
www.streetinsider.com - January 5 at 11:20 AM
First Week of February 16th Options Trading For Idexx Laboratories (IDXX) - NasdaqFirst Week of February 16th Options Trading For Idexx Laboratories (IDXX) - Nasdaq
www.nasdaq.com - January 5 at 11:20 AM
Zacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $491.02 MillionZacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $491.02 Million
www.americanbankingnews.com - January 4 at 5:54 AM
Zacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) to Post $0.73 Earnings Per ShareZacks: Analysts Expect IDEXX Laboratories, Inc. (IDXX) to Post $0.73 Earnings Per Share
www.americanbankingnews.com - January 2 at 5:12 PM
IDEXX Laboratories to Present at J.P. Morgan Healthcare ConferenceIDEXX Laboratories to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 3:52 PM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : January 1, 2018IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : January 1, 2018
finance.yahoo.com - January 1 at 11:06 AM
IDEXX Laboratories, Inc. (IDXX)IDEXX Laboratories, Inc. (IDXX)
finance.yahoo.com - December 31 at 10:49 AM
IDEXX Laboratories (IDXX) Earns Sell Rating from AegisIDEXX Laboratories (IDXX) Earns Sell Rating from Aegis
www.americanbankingnews.com - December 24 at 11:50 PM
Meet TheStreets Pets! They May Be Expensive -- But We Love Them! - TheStreet.comMeet TheStreet's Pets! They May Be Expensive -- But We Love Them! - TheStreet.com
www.thestreet.com - December 23 at 4:14 PM
IDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by AnalystsIDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 2:18 PM
5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now5 Reasons Why You Should Buy Baxter (BAX) Stock Right Now
finance.yahoo.com - December 22 at 11:38 AM
$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$491.02 Million in Sales Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - December 18 at 2:52 AM
IDEXX Laboratories, Inc. (IDXX) Expected to Post Earnings of $0.73 Per ShareIDEXX Laboratories, Inc. (IDXX) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - December 16 at 11:34 PM
IDEXX Laboratories (IDXX) Lowered to "Sell" at BidaskClubIDEXX Laboratories (IDXX) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - December 16 at 8:38 AM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : December 15, 2017IDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : December 15, 2017
finance.yahoo.com - December 15 at 11:56 AM
ETFs with exposure to IDEXX Laboratories, Inc. : December 8, 2017ETFs with exposure to IDEXX Laboratories, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:36 PM
IDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : December 6, 2017IDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : December 6, 2017
finance.yahoo.com - December 6 at 3:36 PM
IDXX Crosses Above Average Analyst TargetIDXX Crosses Above Average Analyst Target
www.nasdaq.com - December 6 at 11:43 AM
IDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : December 5, 2017IDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : December 5, 2017
finance.yahoo.com - December 5 at 12:25 PM
IDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in StockIDEXX Laboratories, Inc. (IDXX) Insider Sells $312,140.00 in Stock
www.americanbankingnews.com - December 4 at 9:02 PM
IDXX Makes Bullish Cross Above Critical Moving Average - NasdaqIDXX Makes Bullish Cross Above Critical Moving Average - Nasdaq
www.nasdaq.com - December 4 at 3:36 PM
Cramer Remix: Amazon may not be as powerful as it seemsCramer Remix: Amazon may not be as powerful as it seems
finance.yahoo.com - December 1 at 5:01 PM
Idexx Laboratories CEO: 'Blockbuster' pet care technology...Idexx Laboratories CEO: 'Blockbuster' pet care technology...
finance.yahoo.com - December 1 at 5:01 PM
Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)
finance.yahoo.com - November 29 at 11:27 AM
$0.73 EPS Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter$0.73 EPS Expected for IDEXX Laboratories, Inc. (IDXX) This Quarter
www.americanbankingnews.com - November 28 at 7:08 PM
ETFs with exposure to IDEXX Laboratories, Inc. : November 27, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 5:25 PM
IDEXX Laboratories, Inc. (IDXX) Receives Consensus Recommendation of "Hold" from BrokeragesIDEXX Laboratories, Inc. (IDXX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 27 at 12:12 PM
IDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 18,000 SharesIDEXX Laboratories, Inc. (IDXX) CEO Jonathan W. Ayers Sells 18,000 Shares
www.americanbankingnews.com - November 16 at 10:33 PM
Cramers lightning round: This is your chance to get into up stock Idexx Labs - CNBCCramer's lightning round: This is your chance to get into 'up stock' Idexx Labs - CNBC
www.cnbc.com - November 15 at 1:22 AM
4 Top Growth Picks to Avoid Tax Tangle in MedTech4 Top Growth Picks to Avoid Tax Tangle in MedTech
finance.yahoo.com - November 14 at 8:15 PM
Cramers lightning round: This is your chance to get into up stock Idexx LabsCramer's lightning round: This is your chance to get into 'up stock' Idexx Labs
finance.yahoo.com - November 14 at 8:15 PM
ETFs with exposure to IDEXX Laboratories, Inc. : November 13, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 7:49 PM
Zacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) Will Post Quarterly Sales of $491.02 MillionZacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) Will Post Quarterly Sales of $491.02 Million
www.americanbankingnews.com - November 12 at 6:46 PM
Zacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) to Announce $0.73 EPSZacks: Brokerages Expect IDEXX Laboratories, Inc. (IDXX) to Announce $0.73 EPS
www.americanbankingnews.com - November 10 at 3:38 AM
Jonathan W. Ayers Sells 54,000 Shares of IDEXX Laboratories, Inc. (IDXX) StockJonathan W. Ayers Sells 54,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock
www.americanbankingnews.com - November 7 at 6:28 PM
IDEXX Laboratories, Inc. (IDXX) CEO Sells $2,767,500.00 in StockIDEXX Laboratories, Inc. (IDXX) CEO Sells $2,767,500.00 in Stock
www.americanbankingnews.com - November 7 at 6:28 PM
Quant Score Make IDEXX Laboratories (IDXX) a BuyQuant Score Make IDEXX Laboratories (IDXX) a Buy
investorplace.com - November 7 at 5:09 PM
IDEXX Laboratories Target of Unusually Large Options Trading (IDXX)IDEXX Laboratories Target of Unusually Large Options Trading (IDXX)
www.americanbankingnews.com - November 5 at 3:18 AM
IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017IDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 2, 2017
finance.yahoo.com - November 4 at 1:53 AM
ETFs with exposure to IDEXX Laboratories, Inc. : November 3, 2017ETFs with exposure to IDEXX Laboratories, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 1:53 AM
IDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity? - Yahoo FinanceIDEXX Laboratories Inc (IDXX): Is It A Good Long Term Opportunity? - Yahoo Finance
finance.yahoo.com - November 3 at 9:11 AM

SEC Filings

IDEXX Laboratories (NASDAQ:IDXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IDEXX Laboratories (NASDAQ:IDXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IDEXX Laboratories (NASDAQ IDXX) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.